Skip to main content

GENERAL COMMENTARY article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1468357

Editorial: Theranostics as a Driving Force in Nuclear Medicine

Provisionally accepted
Steven P. Rowe Steven P. Rowe 1*Rudolf A. Werner Rudolf A. Werner 2Sangeeta Ray Banerjee Sangeeta Ray Banerjee 3
  • 1 University of North Carolina Hospitals, Chapel Hill, North Carolina, United States
  • 2 Goethe University Frankfurt, Frankfurt, Hesse, Germany
  • 3 School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States

This article is a commentary on:

  1. A single-institution experience with 177Lu RPT workflow improvements and qualifying the SPECT/CT imaging for dosimetry

    1. Read original article

The final, formatted version of the article will be published soon.

    Keywords: theranostics, Radiotherapeutics, Endoradiotherapy, PSMA, FAP

    Received: 21 Jul 2024; Accepted: 13 Aug 2024.

    Copyright: © 2024 Rowe, Werner and Ray Banerjee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Steven P. Rowe, University of North Carolina Hospitals, Chapel Hill, 27514, North Carolina, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.